James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, shares insights into a single-center retrospective study evaluating the outcomes of patients with triple-class refractory multiple myeloma, highlighting the promise of novel agents and combinations in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.